MRK Latest Headlines

VYMI vs. SCHD: Which Is the Best Dividend ETF for Passive Income?

at www.tipranks.com (Thu, 23-Jul 11:48 AM)

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Illumina (ILMN)

at www.tipranks.com (Thu, 23-Jul 6:21 AM)

Best ETFs to Invest In, According to AI Analyst, 7/22/2026

at www.tipranks.com (Wed, 22-Jul 2:04 PM)

Merck: ISLEND-Driven HIV Upside Supports Pipeline Re-Rating; Buy Rating Reiterated with Unchanged $141 Price Target

at www.tipranks.com (Wed, 22-Jul 7:15 AM)

Alpha Tau rises on Alpha DaRT head and neck cancer data

at seekingalpha.com (Tue, 21-Jul 9:21 AM)

Dow leadership shifts to value sectors amid broad market rotation

at seekingalpha.com (Mon, 20-Jul 12:08 PM)

Merck Unveils Promising Once-Weekly and Monthly HIV Treatments—Key Data to Be Presented at AIDS 2026

Market Chameleon (Wed, 15-Jul 7:29 AM)

Bullish On MRK? You Might Want To Consider This Credit Put Spread Expiring in 21 Days

Market Chameleon (Thu, 2-Jul 1:09 PM)

Bullish On MRK? You Might Want To Consider This Credit Put Spread Expiring in 10 Days

Market Chameleon (Fri, 26-Jun 12:26 PM)

Merck’s Tulisokibart Marks First Anti-TL1A Success in Phase 3 Ulcerative Colitis Study—Phase 3 Results Show Promise for Immuno-Fibrosis Treatment

Market Chameleon (Mon, 22-Jun 7:53 AM)

Bullish On MRK? You Might Want To Consider This Credit Put Spread Expiring in 15 Days

Market Chameleon (Thu, 11-Jun 11:51 AM)

Bullish On MRK? You Might Want To Consider This Credit Put Spread Expiring in 17 Days

Market Chameleon (Tue, 9-Jun 11:03 AM)

Merck’s KEYTRUDA Plus Padcev Regimen Receives Positive EU CHMP Opinion—A Potential First for Cisplatin-Ineligible Bladder Cancer Patients

Market Chameleon (Fri, 22-May 8:11 AM)

Merck’s Pipeline Progress and Oncology Strength Drive Sales Growth Amid Acquisition-Related Charges

Market Chameleon (Thu, 30-Apr 7:09 AM)